Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year ...

Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...

Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this ...

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for ...

Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices.